![]() ![]() All statements, other than statements of historical facts, contained in this press release, including statements regarding Decibel’s strategy, future operations, prospects, plans, objectives of management, the therapeutic potential for Decibel’s product candidates and preclinical programs, and the potential benefits of cell-selective expression constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. This press release contains forward-looking statements that involve substantial risks and uncertainties. For more information about Decibel Therapeutics, please visit or follow us on Twitter. Decibel’s pipeline, including its lead gene therapy product candidate, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of creating a world of connection for people with hearing and balance disorders. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. McLaughlin.ĭecibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. “I am excited to join the Decibel Board of Directors and to help Decibel continue to advance innovative medicines for the treatment of hearing and balance disorders,” said Mr. McLaughlin received a bachelor’s degree from Northeastern University and an MBA from Babson F.W. He began his career in senior financial roles at Prime Computer and Computervision Corporation. McLaughlin currently serves on the boards of Stealth Bio Therapeutics and Vericel Corporation. ![]() In this capacity he was responsible for negotiating the sale of the company to GSK plc (formerly GlaxoSmithKline). He joined the company as their first CFO later becoming Chief Operating Officer, and then President and Chief Executive Officer and a member of the Board of Directors. McLaughlin held several executive positions with PRAECIS Pharmaceuticals. Prior to Acceleron, he was SVP and CFO of Qteros, Inc., a cellulosic biofuels company from 2009 through 2010 and was co-founder, Chief Operating Officer and director of Aptius Education, Inc., a publishing company, from 2007 through 2009. From 2010 to 2021, he served as Senior Vice President, Chief Financial Officer and Treasurer of Acceleron Pharma until its acquisition by Merck & Co., Inc. McLaughlin has more than 40 years of financial and operating management experience spanning the biotech, high-tech and education industries. “His appointment to the Board provides us with a critical strategic perspective as we continue to build a sustainable gene therapy company to develop innovating new medicines for hearing loss and balance disorders.” He brings a wealth of biopharma experience, including guiding biotech companies through stages of increasing financial and operational maturity,” said Laurence Reid, Ph.D., Chief Executive Officer at Decibel. “We are pleased to welcome Kevin to the Decibel Board. 12, 2022 (GLOBE NEWSWIRE) - Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Kevin F. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |